Top 50 Life Science Startup Investors in Switzerland (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Zürcher Kantonal Bank
VC Fund
|
6 | Switzerland, Germany, Japan | Seed, Series A | Health Care, Biotechnology, Medical Device | $1.2M–$13M |
|
Foundation for Innovation and Technology (FIT)
VC Fund
|
5 | Switzerland, France, United States | Debt Financing, Grant, Seed | Health Care, Biotechnology, Artificial Intelligence | $13k–$1.2M |
|
Eclosion SA
VC Fund
|
4 | Switzerland | Seed, Series C | Biotechnology, Pharmaceutical, Health Care | $1.6M–$28M |
|
EQT Life Sciences
VC Fund
|
4 | United States, The Netherlands, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6.9M–$165M |
|
M Ventures
VC Fund
|
4 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Novartis Venture Fund
VC Fund
|
3 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$120M |
|
Pfizer Venture Investments
VC Fund
|
3 | United States, United Kingdom, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$123M |
|
Verve Ventures
VC Fund
|
3 | Switzerland, Germany, France | Series A, Seed, Series B | Health Care, Software, Biotechnology | $1.4M–$45M |
|
FAST — by GETTYLAB
VC Fund
|
2 | United States, United Kingdom, France | Pre-Seed, Seed | Software, Biotechnology, Health Care | $125k–$5.4M |
|
Lichtsteiner Foundation
VC Fund
|
2 | Switzerland | Seed, Series A | Biotechnology, Health Care, Medical | $1.6M–$6.8M |
|
Indaco Venture Partners
VC Fund
|
2 | Italy, United Kingdom, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Life Science | $3.3M–$110M |
|
SOSV
VC Fund
|
2 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Mergus Ventures
VC Fund
|
2 | Brazil, United States, Chile | Seed, Pre-Seed | AgTech, Aerospace, Biotechnology | $200k–$11M |
|
Rheingau Founders
VC Fund
|
2 | Germany, United States, Poland | Seed, Series A, Pre-Seed | Software, E-Commerce, Internet | $110k–$14M |
|
EFI Lake Geneva Ventures
VC Fund
|
2 | Switzerland, Germany | Seed, Series B, Pre-Seed | Health Care, Life Science, Biotechnology | $2.5M–$16M |
|
SICTIC
VC Fund
|
2 | Switzerland, Germany, Tanzania | Seed, Pre-Seed | Software, Artificial Intelligence, Information Technology | $302k–$3M |
|
BlueOcean Ventures
VC Fund
|
2 | Switzerland, India, France | Seed, Series A, Series B | Health Care, Medical, Personal Health | $1M–$20M |
|
LASP Capital
VC Fund
|
2 | Brazil, United States | Seed, Series A, Pre-Seed | Artificial Intelligence, B2B, FinTech | $800k–$21M |
|
ACE Ventures
VC Fund
|
2 | Switzerland, United States, United Kingdom | Seed, Series A, Pre-Seed | Information Technology, Artificial Intelligence, Life Science | $5M–$18M |
|
Founderful
VC Fund
|
2 | Switzerland, United Kingdom, Canada | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $1.2M–$24M |
|
Sunstone Life Science Ventures
VC Fund
|
2 | Denmark, Sweden, Switzerland | Series A, Series B | Biotechnology, Health Care, Medical | $5.5M–$52M |
|
BioMedPartners
VC Fund
|
2 | Switzerland, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.9M–$83M |
|
VINCI CAPITAL
VC Fund
|
2 | Switzerland, Germany | Series A, Series B | Medical, Health Care, Biotechnology | $8.6M–$36M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
2 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $1.1M–$33M |
|
Kinled Holding
VC Fund
|
2 | United Kingdom, United States, Switzerland | Seed, Series A | Biotechnology, Health Care, Software | $500k–$43M |
|
Fongit Seed Invest
VC Fund
|
2 | Switzerland | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $1.2M–$3.7M |
|
Omega Funds
VC Fund
|
2 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Versant Ventures
VC Fund
|
2 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.7M–$108M |
|
JFG Life Sciences Foundation
VC Fund
|
1 | Switzerland | Seed | Biopharma, Health Care, Biotechnology | |
|
Amboy Street Ventures
VC Fund
|
1 | United States, Canada, Sweden | Series A, Seed, Pre-Seed | Health Care, Wellness, Women's | |
|
Simon Fiduciaria
VC Fund
|
1 | Italy, United Kingdom | Seed, Series B | Therapeutics, Simulation, Biotechnology | |
|
Ysios Capital
VC Fund
|
1 | Spain, United States, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | |
|
Primal Capital
VC Fund
|
1 | Japan, Spain, Switzerland | Seed, Pre-Seed | Software, Information Technology, Internet | |
|
Bruker
VC Fund
|
1 | United States, Switzerland | Series A, Seed | Biotechnology, Medical, Health Care | |
|
Medicxi
VC Fund
|
1 | United States, United Kingdom, The Netherlands | Series A, Series B, Seed | Biotechnology, Health Care, Pharmaceutical | |
|
Horizon 2020
VC Fund
|
1 | Spain, Switzerland, United Kingdom | Grant, Seed | Biotechnology, Health Care, Software | |
|
NEXT VENTŪRES
VC Fund
|
1 | United States, Canada, Finland | Seed, Series A, Series B | Health Care, Wellness, Medical | |
|
Excellis
VC Fund
|
1 | Switzerland, United Kingdom | Series A, Seed, Series B | Internet of Things, Medical, Chemical | |
|
Qiming Venture Partners
VC Fund
|
1 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | |
|
Nicolas Mermod
Angel
|
1 | Switzerland | Series A | Medical, Health Care, Life Science | |
|
Lukas Speiser
Angel
|
1 | Germany, Switzerland | Seed | Wellness, Nutrition, Health Care | |
|
Igor Fish
Angel
|
1 | Switzerland | Series A | Medical, Health Care, Life Science | |
|
Idinvest Partners
VC Fund
|
1 | France, United States, Spain | Series B, Series A | Biotechnology, Software, Health Care | $3.3M–$66M |
|
Acequia Capital (AceCap)
VC Fund
|
1 | United States, United Kingdom, Switzerland | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, Information Technology | $575k–$25M |
|
HBM Healthcare Investments
VC Fund
|
1 | United States, China, Switzerland | Series B, Series C, Series D | Biotechnology, Health Care, Medical | $5.5M–$220M |
|
Founderful Campus
VC Fund
|
1 | Switzerland, Bulgaria, United States | Pre-Seed, Convertible Note, Seed | Artificial Intelligence, Information Technology, Software | $21k–$2.9M |
|
VI Partners
VC Fund
|
1 | Switzerland, Germany, United States | Series A, Series B, Seed | Health Care, Biotechnology, Software | $1.3M–$41M |
|
Beat Schillig
Angel
|
1 | Switzerland | Seed, Series A | Information Technology, SaaS, Music | $2.3M–$5.2M |
|
NEST pension fund
VC Fund
|
1 | Switzerland | Seed, Series A | Health Care, Biotechnology, Medical | $2.1M–$3.5M |
|
Tobias Reichmuth
Angel
|
1 | Switzerland | Seed, Angel, Pre-Seed | E-Commerce, Travel, Internet | $138k–$1.9M |
| Access all 198 investors in Switzerland Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Series A
- Geography: Switzerland, Germany, Japan
Investor stats
- Total investments: 195
- Round size: Seed $1.2M–$6M; Series A $2.3M–$13M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Riverkin — Riverkin builds rugged, low-cost water sensor systems for rivers that measure turbidity and temperature in real time. Our platform turns field data into clear insights and decision making tools.
- QualySense — QualySense is a Swiss start-up company focused on innovative high-throughput grain, beans and seeds sorting technology. QualySense develops a high-speed multi-tons per hour sorting device, which will change how grains, beans and seeds are processed and valued worldwide by assessing the biochemical quality of grains one by one. The QualySensesorters will enable customers to separate grain batches into different biochemical quality classes and sell the corresponding premium products at higher average prices. Food processors will be able to considerably increase the production value, and produce higher quality products in a non-interrupted process.
- Pearltec AG — Headquartered in Schlieren / Zurich, Pearltec AG develops, produces and delivers solutions for the optimal storage, fixation and positioning of patients. Their products are based on unique, patented technology developed in collaboration with ETH Zurich and renowned university hospitals.They have set theirselves the goal to use the technologycompetence of Pearltec AG for the benefit of humans, animals and industry and to create added value for their customers by excellent quality and convincing application advantages.Pearltec AG is certified according to ISO standard 13485. This certification certifies that their quality management system for the development and manufacture of medical devices meets the highest international standards.
The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Artificial Intelligence
- Stage:Debt Financing, Grant, Seed
- Geography: Switzerland, France, United States
Investor stats
- Total investments: 190
- Round size: Seed $117k–$1.2M; Grant $13k–$125k; Debt Financing $107k–$583k
- Lead/follow: 93% lead, 7% follow
Portfolio highlights
- Phonemia — Phonemia is a digital health company that offers artificial intelligence and speech therapy services.
- EM Path Tech — EM Path offers a cutting-edge radio frequency testing solution that caters to the needs of antenna and wireless system providers across diverse industry sectors. Our clients include Consumer Electronics, Antenna Component Providers, Automotive Radar Manufacturers, Radio Telescope Facilities, and Satellite Communication Companies. Our innovativesolution excels in streamlined data acquisition, eliminating the necessity for laborious point-to-point scanning of antennas. This not only enhances efficiency but also provides a competitive edge in the market. EM Path received supports from HEIG-VD, FIT, Venture Competition, VentureKick and Innosuisse.
- DiverSsiTy SA — DiverSsiTy SA develops personalized, patient-centric digital health technologies (DHTs) to improve the lives of patients suffering from neurodevelopmental disorders (NDDs), among which are those with autism spectrum disorder (ASD) and related comorbidities like attention-deficit/hyperactivity disorder (ADHD).
Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Seed, Series C
- Geography: Switzerland
Investor stats
- Total investments: 16
- Round size: Seed $1.6M–$2.7M; Series C $20M–$28M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
- Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
- MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, The Netherlands, Switzerland
Investor stats
- Total investments: 181
- Round size: Series A $6.9M–$77M; Series B $12M–$110M; Series C $12M–$165M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $266M in 2023
Portfolio highlights
- ActoGeniX — ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.
- Rotation Medical — Rotation Medical Inc. manufactures and markets a collagen scaffold for rotational cuff disease in Minnesota. The company was formerly known as Denali Medical Inc. and changed its name to Rotation Medical Inc. in March 2010. Rotation Medical was founded in 2009 and headquartered in Plymouth, Minnesota.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 170
- Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Future Fertility — OUR AI-POWERED ASSESSMENTS GUIDE PERSONALIZED FERTILITY TREATMENT DECISIONS IN OVER 180 CLINICS ACROSS 32 COUNTRIES
- ApoGen Biotechnologies — ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapieseventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 217
- Round size: Series A $5.1M–$81M; Series B $11M–$120M; Series C $9M–$75M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- Bionano Genomics — Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome.
- Protego Biopharma — Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 169
- Round size: Series A $10M–$100M; Series B $20M–$123M; Series C $15M–$102M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $600M in 2018
Portfolio highlights
- VitaDAO — Join VitaDAO, a community owned collective funding early stage longevity research. We fund and commercialize longevity therapeutics.
- Ixchelsis — Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE. To date IX-01 has completed a Phase 1 single ascending dose studyin healthy male volunteers and is currently being progressed through to clinical proof of concept (POC). Ixchelsis is funded by TVM Life Sciences Ventures VII and is lead by an excellent Management team with extensive experience in pharmaceutical R&D, particularly in the male sexual health therapeutic area.
- Flexion Therapeutics — Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 273
- Round size: Seed $1.4M–$12M; Series A $2.6M–$18M; Series B $4.2M–$45M
- Lead/follow: 14% lead, 86% follow
- Last fund: Likely still investing — raised $66M in 2022
Portfolio highlights
- Kiutra — We provide cryogen-free cooling systems that simplify low-temperature research. Our solutions offer fast cooldowns, automated control and millikelvin performance ideal for quantum technologies and material science.
- Sleepiz — Sleepiz is a Zürich based startup with the aim to enable the medical community to take healthcare into the home environment. Sleepiz provides an easy and comfortable to use solution with a device that is simply placed on the bedside table. The device operates in a non-contact fashion and measures movements originating from heart contractions andbreathing patterns as well as body motions with medical grade accuracy.By making use of wireless millimeter wave technology, sensor fusion and artificial intelligence Sleepiz will in the future not only able to diagnose sleep disorders, but also to perform long-term monitoring. Thereby, the progression of chronic diseases can be monitored to allow faster intervention and better treatment.
- Clinpal — Backed by over 30 years of scientific discovery and validation, Cambridge Cognition offers the end-to-end platform for CNS clinical trials.
Backing engineers building awe, wonder, speed.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Pre-Seed, Seed
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 101
- Round size: Seed $1.9M–$5.4M; Pre-Seed $125k–$2.9M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Modelwise — Automated functional safety analysis via drag & drop. Seamless Integration. Faster Analyses. Zero Defects. More Savings.
- Fluent Metal — Fluent Metal is a company that makes metal 3D printing economical, efficient, and safe.
- Integrated Reasoning — Integrated Reasoning builds computer hardware to efficiently solve optimization problems. We're making faster and cheaper to solve problems like scheduling airline pilots or packing boxes into trucks.
Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 10
- Round size: Seed $1.6M–$6.8M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Hemostod — Developing universal platelets and next-generation diagnostics
- DigeHealth — DigeHealth's approach to monitoring gut health using bowel noises and body measurements could provide some really valuable insights into digestive well-being.
- Allegria Therapeutics — Allegria Therapeutics operates as a biotech company.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!VENTURE We invest across all sectors with specific focus on technology and digital The largest independent more About Us Portfolio [...]
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B, Series C
- Geography: Italy, United Kingdom, Switzerland
Investor stats
- Total investments: 47
- Round size: Series A $3.3M–$31M; Series B $8.8M–$89M; Series C $16M–$110M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Newcleo — newcleo is the clean and safe nuclear technology company. Privately funded and headquartered in London, UK, newcleo was launched in 2021 to be a disruptor in the field of nuclear energy. Its mission is to generate safe, clean and inexhaustible energy for the world, through a radically innovative combination of existing, accessible technologies.newcleo is building the next generation system with the goals to: (1) eliminate the need for geological repositories by using a fast neutron flux avoiding production of long life radioactive elements; (2) develop an Accelerator Driven System (ADS), based on the intrinsically safe coupling of a particle accelerator and a sub-critical reactor; (3) accelerate the development of new fuel cycles, including thorium, that provide economic, clean, safe and inexhaustible energy from nuclei and the opportunity to burn the long-lived nuclear waste produced by the old generation of nuclear reactors.With visionary co-founders, newcleo brings together a team of engineers with deep knowledge of nuclear energy with younger recruits with a fresh mindset, working to design an innovative micro Lead Fast Reactor with significant commercial applications, for example in shipping. newcleo wants to be the first step toward the evolution of its industry to become fully respectful of people and the environment. To develop a new, sustainable, and completely safe way of generating nuclear energy that will lead humanity to zero emissions, and to the mitigation of global warming.
- Easy Rain — Leading a new automotive era: our modular ecosystem of virtual sensors and active hardware makes cars and autonomous platforms truly safe in every condition.
- Iama Therapeutics — At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Investing in unconventional founders solving challenges with cutting-edge, future-forward technologies.
Show more...Investment focus
- Industry: AgTech, Aerospace, Biotechnology
- Stage:Seed, Pre-Seed
- Geography: Brazil, United States, Chile
Investor stats
- Total investments: 26
- Round size: Seed $800k–$11M; Pre-Seed $200k–$500k
- Lead/follow: 8% lead, 92% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Spaceium — Spaceium develops a spacecraft docking system to support interplanetary missions. Its docking mechanism aims to offer solutions in the fields of In-space refueling with sustainable fueling stations can be an essential part of space exploration. The company's service hubs efficiently store and transfer cryogenic (extremely cold) andnon-cryogenic fuels with zero loss during storage and transfer.
- Starcloud — Starcloud is building a network of megawatt-scale data centers in space, scaleable to gigawatt capacity. Falling launch costs allow Starcloud to take advantage of the abundant energy, passive cooling, and high-speed connectivity in space.
- Starcloud — Lumen Orbit provides in-orbit cloud computing and data relay for satellites.
Rheingau Founders is a Berlin&Munich based Venture Capital firm active since 2011. Focusing on pre-seed to Series A investments in Europe, predominantly B2B in the fields of Marketplaces, Software as a Service, InsurTech, and eHealth. Rheingau targets start-ups that have the potential to sustainably disrupt existing processes and value chains.Besides the financial investment, we offer strategic support through the mentorship of our partners.
Show more...Investment focus
- Industry: Software, E-Commerce, Internet
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, United States, Poland
Investor stats
- Total investments: 84
- Round size: Seed $110k–$6.3M; Pre-Seed $770k–$2.9M; Series A $2.4M–$14M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- MoleQlar — MoleQlar is a data and research-driven longevity company. It provides valuable information and offers consumers lab-tested nutritional supplements. The company focuses on functional medicine with optimized nutrition. Their product range includes Uthever NMN, Resveratrol, Betaine, Carnosine, and more. These products are aimed at lowering biologicalage and promoting health and longevity. MoleQlar also offers health tracking services. The company is certified in Germany and delivers its products EU-wide, including Switzerland.
- Qualifyze — Qualifyze (former ChemSquare) was founded out of the Technical University of Darmstadt in September 2017. Today, we are based in Frankfurt am Main, the heart of Germany’s pharmaceutical cluster, where the leading life science companies are based. Our team consists of 16 people with diverse backgrounds and areas of expertise in business,engineering, and technology as well as several strategic partners from the pharma, food and cosmetics industry.
- Akhetonics — Creating the first all-optical RISC Processor
EFI Lake Geneva Ventures is a seed and early-stage investment strategy based in Geneva, Switzerland. Founded in 2020, our mission is to foster innovation by investing at an early stage in fast-growing innovative Swiss companies in Technology, Life Sciences and Medtech.
Show more...Investment focus
- Industry: Health Care, Life Science, Biotechnology
- Stage:Seed, Series B, Pre-Seed
- Geography: Switzerland, Germany
Investor stats
- Total investments: 7
- Round size: Seed $2.5M–$3.8M; Series B $5.1M–$16M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Hemotune — hemotune develops a revolutionary medical device for blood purification to provide the means to treat critically ill patients and save lives.
- Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
- Annaida Technologies — Empowering fertility providers and researchers with AI-driven metabolomic platforms. Non-invasive, real-time insights at the microscale for personalized medical treatments.
SICTIC is the leading angel investor network in Switzerland with the largest Swiss seed-stage startup dealflow.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Switzerland, Germany, Tanzania
Investor stats
- Total investments: 210
- Round size: Seed $583k–$3M; Pre-Seed $302k–$2.1M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Agrinorm — Agrinorm is a Swiss deep tech company leveraging cutting edge machine learning techniques for the optimization of fruits and veg supply chains.
- hypt — hypt is a Swiss based SaaS marketing solution that empowers companies to digitalize word-of-mouth. By using our word-of-mouth manager companies are able to activate 40% of their customers to send out a personal recommendation to their peers increasing sales through word-of-mouth by 4 times. Our solution empowers our ICP customers in the finance andinsurance segments to strategically use and optimize the most authentic and cost effective advertising channel – word-of-mouth – and makes it an accessible asset of every marketing mix.
- Get More Brain — Digital learning platform connecting learners and their employers with teachers and schools, publishers and EdTech companies. Marketplace for learning content and learning related services.
BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.
Show more...Investment focus
- Industry: Health Care, Medical, Personal Health
- Stage:Seed, Series A, Series B
- Geography: Switzerland, India, France
Investor stats
- Total investments: 17
- Round size: Seed $1M–$3M; Series A $2.3M–$20M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Augurix — Just another WordPress site
- Mikajaki — Mikajaki is an innovative automated multi-patient ocular diagnostics platform. The platform enables the use of digital technology, robots, AI, and data, allowing patients and eye specialists access to the specific treatment they require. Mikajaki is currently collaborating with ophthalmology clinic groups across the world to test and implementEyeLib.
- official.fm — At Official.fm, they develop powerful music promotion tools for you, whether you're an emerging artist or an accomplished label.They make it easy to manage a few tracks or a large catalog, create pages and players that look like you and share them across your favorite promotion platforms and social networks, all the while collectinginsightful analytics. Improving your workflow is their top priority.Promoting your music with official.fm will always be free. Music promotion is an investment for you and it is one for us too. Now you also have the ability to sell directly music to your fans. Soon they will offer more ways for your to generate revenue from your music.
LASP Capital is a investment firm focuses on global growth companies.
Show more...Investment focus
- Industry: Artificial Intelligence, B2B, FinTech
- Stage:Seed, Series A, Pre-Seed
- Geography: Brazil, United States
Investor stats
- Total investments: 20
- Round size: Seed $800k–$6M; Pre-Seed $2.4M–$5.3M; Series A $6.5M–$21M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Velotax — Velotax is the easiest way to keep customers' income tax information in an organized and centralized way.
- Nuvia — Nuvia is an artificial Intelligence automation platform that helps with sales process, lead generation and hyper-personalized conversions
- Neofin — AI-powered software for B2B payments workflows that automates and streamlines financial processes, transforming the way companies get paid and pay their bills
ACE Ventures is a Swiss-based, early-stage VC firm partnering with the next generation of Swiss tech founders who are building transformative businesses, both in Switzerland and abroad.
Show more...Investment focus
- Industry: Information Technology, Artificial Intelligence, Life Science
- Stage:Seed, Series A, Pre-Seed
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 7
- Round size: Seed $5M–$8M; Series A $6M–$18M
- Lead/follow: 71% lead, 29% follow
Portfolio highlights
- Veezoo — Veezoo empowers individuals to find actionable insights from data by literally just asking questions in plain English!
- Scholé — AI-native personalized learning
- Adaptyv Biosystems — Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and nanofluidics.
Founderful operates as a venture capital firm and a Switzerland’s leading pre-seed fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Switzerland, United Kingdom, Canada
Investor stats
- Total investments: 101
- Round size: Seed $1.5M–$16M; Pre-Seed $1.2M–$3.8M; Series A $3.4M–$24M
- Lead/follow: 55% lead, 45% follow
- Last fund: Likely still investing — raised $85M in 2024
Portfolio highlights
- AVIAN —
- Calvin Risk — We help companies manage the risks of their AI algorithms!
- Stellar Alpina — Stellar Alpina is a Zurich-based space propulsion startup developing rotating detonation rocket engines for mobility after launch.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 60
- Round size: Series A $5.5M–$43M; Series B $9.6M–$52M
- Lead/follow: 17% lead, 83% follow
- Last fund: May invest from a new fund soon — raised $94M in 2019
Portfolio highlights
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
- Resalis Therapeutics — Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 87
- Round size: Series A $5.5M–$31M; Series B $4.9M–$83M; Series C $5.8M–$48M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $113M in 2018
Portfolio highlights
- T-CURX — T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designedto improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care.
- iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operationalbackground in growth, turn-around, consolidation, IPOs and M&A situations.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Series B
- Geography: Switzerland, Germany
Investor stats
- Total investments: 15
- Round size: Series A $8.6M–$20M; Series B $21M–$36M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $10M in 2012
Portfolio highlights
- Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
- SENSIMED — Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.
- Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 583
- Round size: Seed $1.1M–$7.3M; Series A $3.5M–$33M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- DcubeD — Accelerate your space exploration through durable and affordable Release Actuators, Solar Arrays, and Deployables from DCUBED.
- FINE Legal — fine. holt Dir Dein Geld einfach, digital und ohne Risiko.
- NAVAN Technologies — NAVAN Technologies, Inc., (NAVAN) is a pre-clinical stage biotechnology company developing and commercializing its proprietary NanoStraw platform technology, which establishes a direct, physical connection into cells to overcome a huge challenge faced by researchers globally: delivering material into hard-to-transfect-cells in an efficient yetgentle and non-perturbative manne
Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 133
- Round size: Seed $500k–$11M; Series A $2M–$43M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Esper — Esper is the first cloud-based platform to help governments proactively manage public policy with better data and transparency.
- Varda — Expanding the economic bounds of humankind with the world's first orbital manufacturing & reentry platform.
- PreComb — PreComb develops technologies to optimally adapt the therapies to each patient for difficult to treat cancers to increase the success rates in cancer therapy. Only an efficient use of healthcare resources can lead to a maximum improvement in the quality of life of patients.
Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 9
- Round size: Seed $1.2M–$1.4M; Series A $2.3M–$3.7M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
- Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
- Annaida Technologies — Empowering fertility providers and researchers with AI-driven metabolomic platforms. Non-invasive, real-time insights at the microscale for personalized medical treatments.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 154
- Round size: Series A $16M–$197M; Series B $35M–$162M; Series C $14M–$208M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Attenua — 100% satisfaction guaranteed. Hassle-free shopping. We help you find the right domain name.
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 287
- Round size: Series A $4.7M–$84M; Series B $10M–$105M; Series C $12M–$108M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Graphite Bio — Graphite Bio is a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases
- Lycia Therapeutics — Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.
- Nested Therapeutics — Nested Therapeutics is a Cambridge-based VC-backed stealth biotech company. The company's focus is on finding and creating new precision oncology small-molecule drugs targeted toward cancer genes. Nested Therapeutics was established in 2021 in Cambridge, Massachusetts.
JFG Life Sciences Foundation is a non-profit foundation.
Show more...Investment focus
- Industry: Biopharma, Health Care, Biotechnology
- Stage:Seed
- Geography: Switzerland
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Invasight — Invasight is a clinical biotech company that focused on revolutionizing cell invasion research. The company was founded in 2019 and is headquartered in Zurich, Switzerland.
- NXI Therapeutics — NXI Therapeutics - Creating Tomorrow's Immunotherapies | The beginning of a new era of specificity and safety in the immunosuppressive therapy market
Amboy Street Ventures focuses on sexual health and women’s health technology startups. Amboy Street Ventures was founded in 2021 and was headquartered in Los Angeles, USA.
Show more...Investment focus
- Industry: Health Care, Wellness, Women's
- Stage:Series A, Seed, Pre-Seed
- Geography: United States, Canada, Sweden
Investor stats
- Total investments: 17
- Lead/follow: no public data
Portfolio highlights
- Juniper Genomics — Juniper Genomics is shaping a better future for aspiring parents by enabling a faster, more successful IVF journey.
- Nest Health — Nest Health is a primary care company that offers whole person, whole family care for families from birth through age five in urban areas. Nest offers primary and pediatric care for families, made affordable and convenient.
- Allswell — Allswell is a queer-founded mental health platform dedicated to making affirming, accessible care available to the LGBTQ+ community, covered by Medicaid & major insurance.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Simon Fiduciaria nasce nel 1986 per prestare servizi fiduciari a importanti gruppi familiari, imprenditori e professionisti, a livello nazionale ed estero.
Show more...Investment focus
- Industry: Therapeutics, Simulation, Biotechnology
- Stage:Seed, Series B
- Geography: Italy, United Kingdom
Investor stats
- Total investments: 7
- Lead/follow: no public data
Portfolio highlights
- MgShell — MgShell offers intraocular devices for the treatment of age-related macular degeneration and other ocular diseases. Their technology is the only technical solution capable of replicating current clinical practice with a single injection and releasing the same therapeutic drug doses at predetermined periods, autonomously and without surgicalprocedures.
- Soource — Soource is a B2B Saas product that uses AI applications to help purchasing managers to discover the best market solutions through extensive global research and automated email negotiations with thousands of suppliers worldwide.
- Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Spain, United States, Switzerland
Investor stats
- Total investments: 77
- Lead/follow: no public data
Portfolio highlights
- ReproNovo — New Scientific Approaches in Reproductive Medicine. At ReproNovo, we are passionate about bringing the dream of parenthood to life.
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Primal Capital, an independent venture capital " incubator bait fund at ", served as the Associate than July 2012 Hiroshi was Sasaki is the venture capital fund that serves as the representative partner. Representative of Sasaki, the seed acceleration program "Incubate Camp" operated by Incubate bait fund is carried out a totalof four times of planning and management than in 2012, They have also engaged in support operations of portfolio companies. - See more at: https://www.crunchbase.com/organization/primal-capital#sthash.m2z1DCbt.dpuf
Show more...Investment focus
- Industry: Software, Information Technology, Internet
- Stage:Seed, Pre-Seed
- Geography: Japan, Spain, Switzerland
Investor stats
- Total investments: 30
- Lead/follow: no public data
Portfolio highlights
- Hivello — Hivello is a Decentralized Physical Infrastructure Network aggregator. Contribute resources, connect with Web3 protocols, and effortlessly generate passive income.
- RemitAid — RemitAid is a fintech company that operates an overseas payment platform for cross-border transactions between companies.
- xCARE — xCARE specializes in the development and commercialization phases of the pharmaceutical and medical device industries.
Bruker Corporation is a provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed
- Geography: United States, Switzerland
Investor stats
- Total investments: 11
- Lead/follow: no public data
Portfolio highlights
- KIYATEC — Kiyatec is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D cell culture technology platform. Kiyatec works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors.
- Terrain Bio — Terrain Bio helps RNA therapeutics companies design and build better RNA, faster. Leveraging the latest innovations in protein and RNA design and the deep expertise of its scientific cofounders, Terrain brings unparalleled speed and quality to RNA manufacturing.
- Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.
Medicxi is an investment firm that focuses on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 53
- Lead/follow: no public data
Portfolio highlights
- Curevo — focused on a new generation of adjuvanted subunit vaccines Learn More Our Focus We're dedicated to developing non-mRNA vaccines for unmet medical needs Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines. We focus on one need at a time, allowing us to bring effective and better-tolerated vaccines to market quickly
- D3 Bio — D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path.
- Palladio Biosciences — Palladio Bio is a clinical-stage company developing transformative medicines for orphan diseases of the kidney. The company specializes in the fields of biotechnology, pharmaceutical. and therapeutics. Its products are designed for renal disease, kidney disease, and polycystic kidney disease.The company was founded in 2015 and headquartered inHorsham, Pennsylvania.
The EU framework programme for research and innovation
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Grant, Seed
- Geography: Spain, Switzerland, United Kingdom
Investor stats
- Total investments: 122
- Lead/follow: no public data
Portfolio highlights
- NovaMea — NovaMea is a cleantech startup that designs and commercializes electrochemical systems for energy storage and conversion.Its purpose is to create technology, services, and products for the storage and conversion of energy using electrochemical processes, as well as to produce, store, sell, and distribute these products and their components.
- Perciv AI — Perciv provides artificial intelligence (AI)-based software solutions to unlock the latent possibilities of radars and allow resilient and economical autonomous systems with Lidar-like performance even in severe weather circumstances.
- Neuron Soundware — Neuron Soundware uses Artificial Intelligence and Machine Learning in combination with the analysis of sound and other physical parameters.
NEXT VENTŪRES is a venture capital firm that invests in the sports, fitness, health, and wellness markets. With established expertise and deep connections in these markets as well as proven financial track records, the NEXT VENTŪRES team is well positioned to create significant value for their investors and their portfolio companies.The firm wasestablished in 2018 and is based in San Francisco, CA
Show more...Investment focus
- Industry: Health Care, Wellness, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, Finland
Investor stats
- Total investments: 27
- Lead/follow: no public data
Portfolio highlights
- Eternal — Traditional primary care isn't made to keep you active. Eternal is, with annual physicals including 100+ biomarkers and a DEXA scan, plus unlimited in-person and virtual visits. Available in San Francisco and New York City.
- Eternal — Traditional primary care isn't made to keep you active. Eternal is, with annual physicals including 100+ biomarkers and a DEXA scan, plus unlimited in-person and virtual visits. Available in San Francisco and New York City.
- Trial Library — At Trial Library, we partner with the oncology community to enable the discoverability of clinical trials for anyone, anywhere.
Excellis is a private investment company focusing on Robotics Automation.
Show more...Investment focus
- Industry: Internet of Things, Medical, Chemical
- Stage:Series A, Seed, Series B
- Geography: Switzerland, United Kingdom
Investor stats
- Total investments: 9
- Lead/follow: no public data
Portfolio highlights
- FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
- MintNeuro — MintNeuro is pioneering the use of semiconductor technology in next-generation neural implants.
- Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 668
- Lead/follow: no public data
Portfolio highlights
- Keystone — Kesytone is a hardware wallet for bitcoin, Ethereum, USDT, BCH, and cryptocurrencies.
- Ronghe Medical — Ronghe Medical is a medical device manufacturer specializing in the design, research and development, production, and sales of high-end medical device systems based on advanced energy ablation technology platforms, delivering innovative therapeutic solutions that enhance clinical precision, improve patient outcomes, and support a wide range ofmedical applications.
- InfStones — Founded in 2018 with offices across three countries and two continents, InfStones is the world's leading blockchain infrastructure provider. Currently, InfStones provides services to large institutional clients around the globe, supporting thousands of nodes on more than 50 public blockchains through its universal platform.
Nicolas Mermod
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Series A
- Geography: Switzerland
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- NewBiologix — NewBiologix operates as a technology innovation company, develops a proprietary and breakthroughDNA integration platform for the advanced engineering of human and mammaliancell lines.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Lukas Speiser is the founder and CEO of Amorana.ch
Show more...Investment focus
- Industry: Wellness, Nutrition, Health Care
- Stage:Seed
- Geography: Germany, Switzerland
Investor stats
- Total investments: 4
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- feey — feey is a houseplant shop. They offer plants that include entry-level plants, baby plants, animal-friendly plants, large plants, home office plants, hanging plants, aglaonema, alocasia, calathea, hoya, monstera, and philodendron.
- Sleepiz — Sleepiz is a Zürich based startup with the aim to enable the medical community to take healthcare into the home environment. Sleepiz provides an easy and comfortable to use solution with a device that is simply placed on the bedside table. The device operates in a non-contact fashion and measures movements originating from heart contractions andbreathing patterns as well as body motions with medical grade accuracy.By making use of wireless millimeter wave technology, sensor fusion and artificial intelligence Sleepiz will in the future not only able to diagnose sleep disorders, but also to perform long-term monitoring. Thereby, the progression of chronic diseases can be monitored to allow faster intervention and better treatment.
- Dunatura — Dunatura engages in the manufacture and supply of vitamins and micronutrients.
Igor Fish
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Series A
- Geography: Switzerland
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- NewBiologix — NewBiologix operates as a technology innovation company, develops a proprietary and breakthroughDNA integration platform for the advanced engineering of human and mammaliancell lines.
Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series B, Series A
- Geography: France, United States, Spain
Investor stats
- Total investments: 252
- Round size: Series A $3.3M–$24M; Series B $7.8M–$66M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $88M in 2021
Portfolio highlights
- LumApps — LumApps is the only intranet packaged solution that enables employees to feel connected to their organization and engaged in their work from anywhere by delivering a modern, smart digital headquarters that empowers your employees to design a work experience that works for them.
- Ornikar — Ornikar is an online driving school that offers radically cheaper, uncomplicated and faster offer to obtain a driving license.Ornikar relies on a network of state-qualified teachers to offer an apprenticeship in mobile driving at reduced prices. The cmpany is an an online driving school more in tune with the demand of current and futuregenerations.The company's mission is to make the driver's license exam cheaper and its learning more enjoyable.
- Pretty Simple — Video games studio based in Paris, France. Makers of Criminal Case and Sorcery School.
We are a leading early-stage investment platform. We are at the center of a global ecosystem that attracts and fuels the technical founders and product teams building the next wave of global businesses.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 234
- Round size: Seed $1.3M–$8M; Pre-Seed $575k–$3.4M; Series A $5M–$25M
- Lead/follow: 6% lead, 94% follow
- Last fund: May invest from a new fund soon — raised $4M in 2019
Portfolio highlights
- Corintis — Corintis develops cooling technologies for high performance semiconductors.
- Rapidata — Fast and reliable data labeling that powers your AI. Define your label needs now and get the results in minutes.
- Applied Atomics, Inc. — Co-located nuclear power plants to unlock the next 1,000 years of advanced industry.
As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The companyfocuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series D
- Geography: United States, China, Switzerland
Investor stats
- Total investments: 199
- Round size: Series B $9.8M–$165M; Series C $5.5M–$183M; Series D $20M–$220M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
- CellCentric — CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
- Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
Founderful Campus aims to educate students and support entrepreneurs to disrupt the startup culture on campuses, producing the next generation of tech leaders, and creating more value for society.
Show more...Investment focus
- Industry: Artificial Intelligence, Information Technology, Software
- Stage:Pre-Seed, Convertible Note, Seed
- Geography: Switzerland, Bulgaria, United States
Investor stats
- Total investments: 30
- Round size: Seed $2.3M–$2.9M; Pre-Seed $21k–$2.9M; Convertible Note $21k–$31k
- Lead/follow: 73% lead, 27% follow
Portfolio highlights
- Forgis — Forgis is leading the next industrial revolution by introducing industrial intelligence into factories, which boosts the competitiveness of Western manufacturing.
- Impact.build — Impact Build transforms excavated earth into low-carbon building elements using advanced robotic manufacturing, delivering circular construction that competes on both cost and performance.
- Aurora Analytics — Track and optimize your brand visibility across AI search engines. The leading GEO tracking and AI search optimization platform.
Vi Partners is a venture capital firm backing exceptional founders in healthcare and technology across Switzerland and Europe for over 25 years.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Seed
- Geography: Switzerland, Germany, United States
Investor stats
- Total investments: 111
- Round size: Seed $1.3M–$6.5M; Series A $3.7M–$24M; Series B $3.3M–$41M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $117M in 2020
Portfolio highlights
- Equippo.com — Used construction equipment marketplace. Easy and safe. Only inspected machines. Worldwide delivery. Money Back Guaranteed. Buy Now, Pay Later!
- Nexthink — Discover what your employees need, see what they experience, know how they feel. Deliver IT that delights.
- Pay by Shopping (deal united) — paybyshopping.com Domain Name is available to Buy. Grab this great Domain from Daaz. Daaz has the lowest transaction fees in the industry. See our list of GTLD's,CCTLD's, New GTLD's,3N's, 6N's, 3L's, 6L's etc.
Beat Schillig - Founder @ Venture Kick
Show more...Investment focus
- Industry: Information Technology, SaaS, Music
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 3
- Round size: Seed $2.3M–$5.2M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- TYXIT — TYXIT is linking musicians wirelessly without configuration, allowing a personal audio monitoring.
- PXL Vision — PXL Vision enables state-of-the-art digital identity verification. PXL Vision's highly flexible technology solution helps global customers build trust digitally...
- 1Drop Diagnostics — 1Drop Diagnostics is a cutting edge medical diagnostics and life science company. They combine the best techniques from microfluidics, biochemistry, photonics and information technology to build high performance point-of-care diagnostics devices.Their vision is to provide high quality medical information for everyone. They aim to increase accessto quality healthcare by providing laboratory quality, easy to use, medical diagnostics in any setting. The 1Drop Diagnostics system is being developed for a broad menu of clinical applications including multiplexed assays of proteins, nucleic acids and peptides. Their first clinical applications are in the screening, diagnostics and monitoring of cardiovascular disease and infectious disease.Their mission is to improve patient lives by enabling precision medicine through non-invasive diagnostic tests providing actionable health information that is accessible to everyone at any time. They facilitate the early detection, prevention and management of disease. They empower people to live better lives.
For more than 35 years, Nest, as the first ecological and ethical pension fund in Switzerland, has remained true to its guiding principle: the optimal provision for the companies affiliated with us and their employees.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 3
- Round size: Seed $2.1M–$3.5M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Piomic — There are about 50 million reported cases of patients suffering from hard-to-heal wounds, which has created a severe cost burden on global healthcare systems.The COMS® One Therapy System is a portable, hand-held device which incorporates the technologies for optical and magnetic stimulation, intended to promote wound healing in chronic leg andfoot ulcers.The pivotal clinical study showed that the treatment is safe, leads to accelerated wound closure, overall reduced pain and increased quality of life. The easy-to-use, single button operated device integrates smoothly into the patient’s healing journey with usage in stationary and ambulant facilities but also in patient’s home.By developing a therapy which is safe and effective we hope to set a better future for patients in need.
- Comphya — Comphya developing an active implantable medical device to restore the erectile function of patient non-responsive to oral drugs.
- Nagi Bioscience — Enabling small organisms testing to any lab. Unleash unique datapoints efficiently at a high-throughput rate.
Tobias Reichmuth - Founding Partner at Maximon - The Longevity Company Builder @ Maximon
Show more...Investment focus
- Industry: E-Commerce, Travel, Internet
- Stage:Seed, Angel, Pre-Seed
- Geography: Switzerland
Investor stats
- Total investments: 7
- Round size: Seed $350k–$1.9M; Angel $138k–$1.7M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- Firstcar — Firstcar provides car driving learning assistant services. They offer services that include hand-picked driving schools, student cars with double pedals for rent before and for the driving test, entry-level vehicles that are inexpensive to buy and maintain, support and advice on vehicle purchase, and selected insurances with special rates.
- MyFeld.ch — MyFeld.ch is the holder of a fresh farm food platform that aims to create a digital link between consumers and our local agriculture. The company's platform provides products directly from the farm, allowing people to improve their comprehension of seasonality and regionality while also raising awareness of the sustainable use of food byallowing them to purchase fresh produce from the farm.
- Testmate Health — 2 in 1 urine test with immediate results for Chlamydia trachomatis and Neisseria gonorrhoeae. Results within minutes & 100% anonymous.
Life Science Investor funding in Switzerland at a glance
Stats across 143 deals from 198 investors.
Access all 198 investors in Switzerland Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science Investors in Switzerland investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 198 investors investing in Switzerland Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!